InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
17,162.80
(
0.60%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.16
(
0.01%
)
Bitcoin
64,263.79
(
-0.34%
)
Post# of 4273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 82
Posts 12421
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Wednesday, 04/11/2018 8:29:06 AM

Wednesday, April 11, 2018 8:29:06 AM

Post# of 4273
IronWood did $700 million in sales in 2017 which is SGYP’s direct competitor. Recently, the hedge fund ran by Alex Denner, obtained a board seat on IRWD’s board as he feels the company is undervalued and mismanaged. Alex also obtained a board seat on Ariad Pharma as it was being mismanaged by Harvey Berger (CEO). Alex was responsible for Ariad being acquired by Takeda for $5.2 billion, or $24 per share. SGYP is a prime candidate for a hedge fund like Denner’s to become an activist to correct the mismanagement and orchestrate a buyout.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up